News & analysis on the clinical development and manufacture of large molecule drugs
ISPE – Chris Chen
By Ben Hargreaves
- Last updated on
Chris Chen, CEO of WuXi Biologics, becomes the first board member of the International Society for Pharmaceutical Engineering (IPSE) from Asia. He will serve a two-year term on the board of the not-for-profit association that holds a membership of 18,500.
The aim of the association is to provide an environment for members to engage in dialogue on process technologies and technical solutions, as well as the regulatory issues the industry faces.
“ISPE strives to improve manufacturing of quality medicines for global patients. I'm honoured and proud to be part of ISPE's board to engage in the governance and strategic direction of the society, which is a great opportunity for me personally as well as WuXi Biologics,” said Chris Chen.